May 1, 2012
BEAMing Digital PCR Technology applied to blood-based mutation detection in breast cancer patients more >>
Inostics has the goal to improve cancer drug development and standard patient management by offering state of the art molecular diagnostic tools for the non-invasive detection and monitoring of tumors in blood samples.
The core competency of Inostics is centered around the detection of genetic changes, such as somatic mutations, in a patients’ blood or tissue.
BEAMing Technology for the detection of mutations in Plasma/Serum and Tissue. more >>
Exon Sequencing for discovery and detection of mutations from tumor tissue. more >>
Design, implementation and qualification of new companion diagnostics. more >>